10-K: NextPlat Reports 18% Revenue Drop, Nasdaq Delisting Risk Looms

NextPlat Corp reported an 18% decline in net revenue for 2025, alongside a significant net loss, and faces ongoing Nasdaq delisting concerns despite a planned reverse stock split.

Summary

• Net revenue decreased by 18% to $54.3 million in 2025 from $66.1 million in 2024.
• Gross profit declined by 36% to $10.9 million in 2025 from $17.0 million in 2024, with gross margins falling from 26% to 20%.
• Net loss improved by 54% to $10.5 million in 2025 from $22.5 million in 2024, primarily due to the absence of $13.7 million in non-recurring impairment charges from the prior year.
• e-Commerce segment revenue increased by 6% to $14.6 million, while Healthcare Operations revenue decreased by $12.6 million, driven by lower 340B contract revenue and reduced pharmacy prescription revenues.
• The company faces Nasdaq delisting risk due to its stock price falling below $1.00, leading to a shareholder-approved 1-to-10 reverse stock split on March 27, 2026.
• Accumulated deficit reached $60.1 million as of December 31, 2025.
• Identified two unremediated material weaknesses in internal control over financial reporting related to PBM performance bonus receivable estimation and PIPE warrant modification.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing negatively due to significant revenue and gross profit declines, ongoing net losses, and the critical Nasdaq delisting threat requiring a reverse stock split, despite an improved net loss driven by the absence of prior-year impairment charges.

Positives

• Net loss improved significantly by 54% year-over-year, from $22.5 million in 2024 to $10.5 million in 2025, primarily due to the absence of large impairment charges.
• e-Commerce segment revenue increased by 6% to $14.6 million in 2025, driven by growth in airtime and hardware sales and favorable foreign currency impact.
• Remediated a previously identified material weakness in internal control over financial reporting related to inventory valuation.
• Management believes existing financial resources are sufficient to support planned operations for at least one year past the financial statements' issuance date.
• The company has a diverse geographical customer base in e-Commerce, serving over 60,000 customers in more than 165 countries.
• Healthcare operations achieved a Five Stars performance score from EQuIPP, ranking among the top pharmacies in the U.S.

Negatives

• Overall net revenue decreased by 18% to $54.3 million in 2025.
• Gross profit declined by 36% to $10.9 million, and gross margins decreased from 26% to 20%.
• Healthcare Operations revenue, the largest segment, saw a significant $12.6 million decrease, primarily due to a 61% drop in pharmacy 340B contract revenue and a 15% decrease in pharmacy prescription revenue.
• The company incurred an accumulated deficit of $60.1 million as of December 31, 2025, and expects to continue incurring operating losses.
• Cash balance decreased from $19.96 million in 2024 to $13.7 million in 2025.
• Two material weaknesses in internal control over financial reporting remain unremediated as of December 31, 2025, related to PBM performance bonus receivable estimation and PIPE warrant modification.
• The share repurchase program expired on December 16, 2025, and was not extended, with only $0.1 million repurchased out of $2.0 million authorized.
• A deemed dividend of $1.249 million was recognized due to the modification of PIPE warrants.

Risks

• Incurred significant net losses and accumulated deficit, and may require additional capital to continue operations and execute business strategy.
• Unfavorable global economic conditions, inflation, rising interest rates, and financial market volatility could materially adversely affect the business.
• Business may be adversely affected by pandemics, public health crises, natural disasters, acts of war, or other events beyond control.
• Heavy reliance on a single pharmaceutical wholesale distributor (McKesson) for approximately 98% of pharmaceutical purchases.
• Failure to maintain compliance with applicable continued listing standards of The Nasdaq Stock Market, including the Minimum Bid Price Requirement and Market Value Requirement, could lead to delisting.
• The Reverse Stock Split may incentivize stockholders to sell, depress the stock price, or not increase the price over the long term, potentially leading to delisting.
• Business requires significant working capital and is exposed to inventory and receivables risk.
• May not have adequate insurance coverage to protect against all operational and product liability risks.
• Significant dependence on Amazon marketplaces and fulfillment services (31.1% of e-Commerce revenue in 2025).
• e-Commerce operations depend on global suppliers, manufacturers, and logistics providers, with certain products sourced from limited suppliers.
• Operates in highly competitive markets, and technological advances may render products less competitive.
• Changes in reimbursement rates, healthcare regulations, or pharmacy benefit manager practices could materially adversely affect the healthcare segment.
• Subject to extensive and evolving domestic and international laws and regulations, with failure to comply resulting in fines, penalties, litigation, and reputational harm.
• Healthcare operations are subject to audits, investigations, and potential recoupment actions by government agencies and PBMs.
• Failure to comply with laws and regulations governing controlled substances could materially adversely affect operations.
• A significant portion of pharmacy segment gross profit is derived from participation in the federal 340B Drug Pricing Program, and adverse changes to the program could materially adversely affect profitability and cash flows.
• Security breaches or failures in information systems could materially harm the business.
• May incur significant costs and liabilities in connection with data privacy and cybersecurity regulations.
• Growth strategy involves acquisitions and strategic investments that may not achieve expected benefits.
• Operations in China expose the company to political, economic, and regulatory risks, including retaliatory tariffs.
• Being a public company increases costs and administrative burdens.
• Concentration of ownership may limit other stockholders' ability to influence corporate matters.

Future Outlook

Management expects to continue incurring operating losses as it invests in expanding e-Commerce and healthcare operations, develops new platforms and services, and pursues potential acquisitions. The company anticipates funding long-term requirements through cash generated from operations, available cash on hand, and potentially future equity or debt financings. Recurring airtime and service plans are expected to represent an increasing proportion of e-Commerce revenue, and the company plans to develop additional country-specific e-Commerce websites. In healthcare, data management services are projected to gain increasing importance and drive growth. While a reverse stock split is intended to help regain Nasdaq compliance and increase stock price, its long-term effect on the market price cannot be predicted with certainty.

Management Comments

• Our strategy is focused on expanding recurring revenue streams, increasing global e-Commerce distribution, and leveraging healthcare data and pharmacy services to improve patient outcomes while supporting healthcare providers and payors.
• We expect to continue to incur operating losses as we invest in expanding our e-Commerce and healthcare operations, develop new platforms and services, and pursue potential acquisitions.
• Management believes that the existing financial resources are sufficient to continue operating activities for at least one year past the issuance date of the financial statements.
• Management is committed to improving its internal control over financial reporting and remediating the material weaknesses described above as quickly as possible.

Industry Context

StockSavvy.ai notes that NextPlat operates in two distinct yet evolving sectors: global e-commerce for satellite communications and the U.S. healthcare services market. The e-commerce segment benefits from increasing demand for connectivity in remote environments, aligning with broader trends in global connectivity and IoT. However, its heavy reliance on Amazon (31.1% of e-Commerce revenue) exposes it to marketplace policy changes and competition. In healthcare, the company's focus on personalized care, data management (Applied Health Analytics), and 340B Drug Discount Pricing Program participation reflects industry shifts towards value-based care and data-driven patient outcomes. The consolidation trend in the retail pharmacy and pharmaceutical wholesale industries, as mentioned in the filing, presents both competitive pressures and potential acquisition opportunities for NextPlat. The company's high EQuIPP performance score (Five Stars) suggests strong operational quality in its pharmacy services, a key differentiator in a competitive landscape.

Comparison to Industry Standards

• NextPlat's e-Commerce segment competes with other resellers of leading satellite networks such as Iridium, Inmarsat, Thuraya, Globalstar, and Starlink. Its competitive advantage is stated to be cost basis and global e-commerce presence, making products more accessible compared to traditional brick-and-mortar stores.
• In the healthcare sector, NextPlat's pharmacies compete with national and independent retail drug stores, supermarkets, mail order providers, and large, well-capitalized specialty pharmacy companies like CVS Caremark, Express Scripts, Humana, Optum, and Walgreens.
• The company's EQuIPP performance score of Five Stars for its pharmacy operations ranks it among the top pharmacies in the U.S., indicating strong medication adherence and patient care compared to industry peers.
• Some competitors, such as Omnicare and Walgreens, have substantially larger market shares and may have secured more favorable long-term supply or distribution arrangements for pharmaceuticals, potentially giving them a price competitive advantage over NextPlat for certain products.

Management Changes

Corporate Governance

Legal Proceedings

• A former employee of Pharmco LLC filed a lawsuit under EEOC regulations on March 17, 2025, which was settled on October 14, 2025, with the settlement fully covered by the company's insurance policy.
• Alan Jay Weisberg, former CEO of Progressive Care Inc., filed a putative class action suit on October 28, 2024, against NextPlat and two directors, alleging insufficient consideration in the Progressive Care merger; the company believes the claims are without merit and has accrued $1.75 million as a probable loss, covered by insurance retention.
• Progressive Care settled an arbitration proceeding with a former employee on November 7, 2025, paying $150,000 cash and transferring 128,205 shares of NextPlat common stock (valued at $100,000), including a reverse stock-split protection mechanism for the shares.

Related Party Transactions

• Accounts payable due to the company's Chief Executive Officer for American Express accounts (Orbital Satcom and GTC) personally guaranteed by the CEO, totaling $11,000 as of December 31, 2025.
• Wages paid to one employee related to the Chief Executive Officer and one employee related to the Chief Financial Officer during 2025.
• Wages paid to the spouse of the company's late Chief Executive Officer, Charles M. Fernandez, as Chief of Staff and Special Assistant to the Chairman of the Board, until her employment was terminated on August 13, 2025.

Stakeholder Impact

• Shareholders: Face significant dilution risk if additional equity financing is pursued; potential for stock price volatility and further decline due to Nasdaq delisting risk and reverse stock split; concentration of ownership by principal stockholders, executive officers, and directors may limit influence.
• Employees: Reduction in total headcount contributed to decreased salaries, wages, and payroll taxes; potential impact from ongoing operational efficiency measures and cost reductions.
• Customers (e-Commerce): Continued demand for satellite communications products and services; potential for increased product offerings and global distribution.
• Customers (Healthcare): Benefit from high-performance scores (Five Stars from EQuIPP) and value-added services like prior authorization assistance and home delivery; potential impact from changes in provider relationships and insurance network adjustments.
• Suppliers: Heavy reliance on single suppliers (e.g., McKesson for 98% of pharmaceutical purchases, Iridium Satellite, Garmin, Globalstar Europe for e-Commerce) creates risk of disruption or increased costs if relationships change.
• Creditors: Exposure to interest rate risk if additional indebtedness is incurred; potential for penalties or defaults under material agreements if Nasdaq delisting occurs.

Next Steps

• Implement the 1-to-10 reverse stock split approved by the Board of Directors on March 27, 2026.
• Work to maintain the stock price above $1.00 for at least ten consecutive trading days to regain Nasdaq compliance by April 27, 2026.
• Remediate the two unremediated material weaknesses in internal control over financial reporting related to PBM performance bonus receivable estimation and PIPE warrant modification.
• Continue to evaluate strategic alternatives and operational initiatives to strengthen liquidity and support long-term growth.
• Pursue growth through organic expansion and selective acquisitions in e-Commerce and healthcare.
• Target US government/GSA sales and recruit experienced government sales professionals for e-Commerce.
• Develop additional country-specific e-Commerce websites.
• Invest in sales and marketing for healthcare data management and health IT services.
• Vigorously defend against the Alan Jay Weisberg class action lawsuit.

Key Dates

Recommendation

The company reported a substantial 18% decline in net revenue and a 36% drop in gross profit for 2025, indicating deteriorating operational performance despite a lower net loss primarily due to the absence of prior-year impairment charges. The ongoing Nasdaq delisting threat, necessitating a reactive reverse stock split, introduces significant uncertainty and potential for further stock price depreciation. Unremediated material weaknesses in internal controls, heavy reliance on single suppliers and Amazon, and a substantial accumulated deficit of $60.1 million highlight fundamental business challenges and financial instability. These factors collectively suggest a high-risk investment profile with significant downside potential.

Keywords

e-Commerce, Healthcare Services, Satellite Communications, Pharmacy Services, 340B Drug Pricing Program, Nasdaq Delisting, Reverse Stock Split, Cybersecurity Risk Management, Financial Performance, SEC Filing, Annual Report, Risk Factors, Internal Controls, Litigation, Working Capital, Supply Chain, Amazon Marketplace, McKesson, Global Telesat Communications, Progressive Care LLC